Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
$4.80
+13.5%
$3.50
$1.00
$5.87
$42.56M0.65143,331 shs152,522 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.27
+3.3%
$14.24
$5.22
$27.38
$154.00M0.41139,129 shs145,263 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$2.69
-10.3%
$3.06
$1.45
$19.50
$89.30M1.27462,168 shs980,393 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$2.91
-5.2%
$3.11
$2.23
$5.20
$144.43M1.29442,697 shs475,098 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
+13.48%+40.15%+73.91%+12.94%+131.88%
LifeVantage Co. stock logo
LFVN
LifeVantage
+3.15%+3.02%-19.80%-36.46%+84.79%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-10.33%-42.03%+13.98%-45.66%-80.39%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-5.21%-9.35%0.00%+4.68%-39.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
1.9383 of 5 stars
3.33.00.00.02.51.70.0
LifeVantage Co. stock logo
LFVN
LifeVantage
4.0698 of 5 stars
3.51.01.72.72.22.51.3
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.876 of 5 stars
3.61.00.00.03.52.51.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.91 of 5 stars
3.52.00.00.02.63.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00150.00% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50148.57% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
3.17
Buy$22.20725.28% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00140.55% Upside

Current Analyst Ratings Breakdown

Latest ATHE, PBYI, LFVN, and LXEO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $22.00
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/26/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$24.00 ➝ $20.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/24/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $18.00
2/28/2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$212.15M0.73$0.64 per share19.03$2.38 per share5.16
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$650K137.38N/AN/A$4.26 per share0.63
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.47M0.63$0.69 per share4.19$1.12 per share2.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.5621.91N/A3.46%34.29%15.04%N/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$66.39M-$3.08N/AN/AN/AN/A-57.66%-48.18%N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.616.067.66N/A9.56%41.60%10.71%N/A

Latest ATHE, PBYI, LFVN, and LXEO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/24/2025Q4 2024
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.87-$0.78+$0.09-$0.78N/AN/A
2/27/2025Q4 2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.10$0.39+$0.29$0.39$52.50 million$59.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.161.30%N/A28.57%2 Years
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A

Latest ATHE, PBYI, LFVN, and LXEO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/A
3.54
3.54
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
0.01
5.95
5.95
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.46
1.42
1.40

Institutional Ownership

CompanyInstitutional Ownership
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
2.14%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
38.80%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
4.50%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
108.87 million5.35 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.55 million9.96 millionOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5833.20 million31.58 millionNot Optionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million37.45 millionOptionable

Recent News About These Companies

Puma Biotech CCO Jeff Ludwig departs, no replacement named
Zacks Research Brokers Reduce Earnings Estimates for PBYI
Q1 EPS Forecast for Puma Biotechnology Raised by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$4.80 +0.57 (+13.48%)
As of 05/9/2025 03:59 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.27 +0.39 (+3.28%)
As of 05/9/2025 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$2.69 -0.31 (-10.33%)
As of 05/9/2025 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$2.91 -0.16 (-5.21%)
As of 05/9/2025 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.